跳至主要内容
临床试验/CTRI/2018/04/012995
CTRI/2018/04/012995已完成未知

To Study the Immunomodulating Effects and Safety Profile of Ï?3 and Ï?6 PUFA Containing Intravenous Lipid Emulsion in Patients With Acute on Chronic Liver Failure

Institute of liver and Biliary Sciences0 个研究点目标入组 90 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1) Subjects aged 18 years and above
  • 2) Patients tolerating enteral nutrition
  • 3) Patients with no overt sepsis - no fever, sterile blood and urine cultures, procalcitonin <2

排除标准

  • 1) Active ongoing GI bleed
  • 2) Allergy to soya oil, eggs, peanuts or other ingredients of intralipid.
  • 3) Co-morbidities like Diabetes mellitus, hyperlipidemia, CAD and hypothyroidism.
  • 4) Renal failure (S.creatinine > 2.5mg%)
  • 5) Pregnancy
  • 6) Patients with shock requiring vasopressor support
  • 7) Patients on anticoagulants
  • 8) Refusal to participate in the study

研究者

相似试验